A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma

OBJECTIVES: Renal cancer is resistant to most DNA and DNA repair targeted chemotherapy; although moderate response rates to nucleotide analog based therapy have been reported. Bevacizumab also has activity. We thus performed a phase II trial of gemcitabine, capecitabine, and bevacizumab in patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Clin Oncol
Asıl Yazarlar: Chung, Elizabeth K., Posadas, Edwin M., Kasza, Kristen, Karrison, Theodore, Manchen, Elizabeth, Hahn, Olwen M., Stadler, Walter M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644601/
https://ncbi.nlm.nih.gov/pubmed/20395787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d6b2fe
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller